Patents Examined by Kristin A Vajda
  • Patent number: 11371078
    Abstract: The present application relates to new coumarin compounds and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: June 28, 2022
    Assignee: Illumina Cambridge Limited
    Inventor: Nikolai Nikolaevich Romanov
  • Patent number: 11365190
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: June 21, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth Charnley, Gren Z. Wang, Joseph J. Romano
  • Patent number: 11364220
    Abstract: Compounds described herein are inhibitors of retinoic add inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.
    Type: Grant
    Filed: November 26, 2020
    Date of Patent: June 21, 2022
    Assignee: Queen's University at Kingston
    Inventors: Donald Andrew Cameron, Martin Petkovich, Toni Kristian Rantanen, Victor Snieckus, Johnathan Board, Suneel Singh, Ashishkumar Jayantilal Maheta
  • Patent number: 11365174
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: June 21, 2022
    Assignees: Thomas Jefferson University, Ramot At Tel-Aviv University LTD.
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlohr, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • Patent number: 11365198
    Abstract: The present disclosure relates to pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and corresponding methods of treating psoriatic arthritis.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: June 21, 2022
    Assignee: AbbVie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson
  • Patent number: 11357825
    Abstract: A means for treating cardiovascular disease, in particular chronic heart failure, especially in terms of a more specific treatment preventing or minimizing pathological hypertrophic signaling while leaving cardiac contractility largely intact. For this purpose the present invention provides a means for treating cardiovascular disease, in particular chronic heart failure, the means specifically inhibiting or causing inhibition of components of the ?1-AR/cAMP pathway generating cAMP resulting from activation of the ?1-adrenoceptor on the cardiomyocyte cell crest.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: June 14, 2022
    Assignee: Universitaetsklinikum Hamburg-Eppendorf
    Inventors: Viacheslav Nikolaev, Alexander Froese
  • Patent number: 11357750
    Abstract: Described herein are prodrugs of cysteamine and pharmaceutically acceptable salts, solvates, and esters thereof. Also described herein are pharmaceutical compositions comprising prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof, and methods of treatment comprising administering prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: June 14, 2022
    Assignee: Children's Hospital Medical Center
    Inventor: Stephen Perrett
  • Patent number: 11352317
    Abstract: The present disclosure discloses a rosin-based small molecular weight hydrogelator and an application thereof, and belongs to the fields of supramolecular chemistry, surfactant science and chemical utilization of rosin. The rosin-based small molecular hydrogel of the present disclosure can gel water at a very low concentration, and the critical gelling concentration is only 0.176 wt %. On average, each gelling agent molecule can hold 13,889 water molecules, which exhibits extremely high gel efficiency and the formed small molecular hydrogel also exhibits extremely high stability. This small molecule hydrogel is derived from the natural product rosin and has a mild nature. It can be used in the fields of drug sustained-release, tissue engineering, daily chemicals, medicine and so on.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: June 7, 2022
    Assignee: Jiangnan University
    Inventors: Binglei Song, Tingting Yan, Danping Wang, Zhenggang Cui
  • Patent number: 11352318
    Abstract: The present invention provides a production method for dicyanocyclohexane, including a step of obtaining dicyanocyclohexane by reacting cyclohexanedicarboxylic acid and/or a salt thereof, or a heated concentrate of an aqueous ammonia solution of cyclohexanedicarboxylic acid with ammonia in a solvent having a boiling point equal to or higher than a reaction temperature.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: June 7, 2022
    Assignee: Mitsubishi Gas Chemical Company, Inc.
    Inventors: Akifumi Iida, Emi Nakano, Yutaka Kanbara
  • Patent number: 11345668
    Abstract: A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic ?-N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: May 31, 2022
    Assignee: MANNKIND CORP.
    Inventors: John J. Freeman, Otto Phanstiel, William Elliot Bay, Kelly Sullivan Kraft
  • Patent number: 11345683
    Abstract: The present invention provides dibenzylamine salt of Lifitegrast (XV), and diphenylamine salt of Lifitegrast (XVI) and the use of the above salts in the purification process of Lifitegrast (I). The present invention relates to a process for the preparation of Lifitegrast (I).
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: May 31, 2022
    Assignee: Aurobindo Pharma Ltd
    Inventors: Praveen Kumar Neela, Guruswamy Batthini, Vijay Kumar Gupta Gangisetty, Ravikanth Dupud, Srikanth Sai Alur, Sivakumaran Meenakshisunderam
  • Patent number: 11332453
    Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: May 17, 2022
    Assignee: H. LUNDBECK A/S
    Inventors: Cheryl A. Grice, Daniel J. Buzard, Michael B. Shaghafi
  • Patent number: 11331282
    Abstract: The present invention provides an ophthalmic composition and a use thereof. In one embodiment of the present invention, an ophthalmic composition containing a clathrated antioxidant substance is provided. In some of embodiments of the present invention, a composition for treating or preventing an ophthalmic disease, an ophthalmic disorder or an ophthalmic symptom is provided, wherein the ophthalmic disease, the ophthalmic disorder or the ophthalmic symptom includes, but is not limited to, dry eye or a dry eye-like ophthalmic disease, conjunctivitis, corneal ulcer, age-related macular degeneration, cataract, pseudoexfoliation syndrome, and symptoms in these diseases which can be ameliorated by increasing the quantity of tears and/or goblet cells and/or mucin.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: May 17, 2022
    Inventors: Junwen Qin, Yuji Takahashi, Shigeru Kakuta, Shigeru Kyuwa
  • Patent number: 11332494
    Abstract: An oxysterol or oxysterol-like compound is provided, which finds use in treating and/or targeting cancer.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: May 17, 2022
    Assignee: Fernando Thome Kreutz
    Inventor: Fernando Thome Kreutz
  • Patent number: 11331289
    Abstract: The present invention relates to a new topical composition comprising niclosamide and/or oxyclozanide and to the use of said composition for the treatment or prevention of pyoderma or dermatitis in non-human mammals.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: May 17, 2022
    Assignees: CEVA SANTE ANIMALE, UNION THERAPEUTICS A/S
    Inventors: Jérôme Guyonnet, Claudine Zemiriline, Pascal Butty
  • Patent number: 11326165
    Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: May 10, 2022
    Assignee: SKYHAWK THERAPEUTICS, INC.
    Inventors: Michael Luzzio, Kathleen McCarthy, William Haney
  • Patent number: 11325898
    Abstract: Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: May 10, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
  • Patent number: 11318205
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: May 3, 2022
    Assignee: KYMERA THERAPEUTICS, INC.
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Fluge, Matthew M. Weiss, Yi Zhang
  • Patent number: 11318331
    Abstract: Disclosed herein is a therapeutically active agent usable in the treatment of pulmonary arterial hypertension (PAH), for use in the treatment of pulmonary arterial hypertension, as well as methods of treating PAH, said treatment and methods comprising administering such an active agent and effecting pulmonary artery denervation in the subject. In some aspects, a sub-therapeutically effective amount of the active agent is administered. In some aspects, the method is devoid of administering such an active agent for at least one month subsequent to the denervation. Further disclosed is a method of treating PAH comprising determining a responsiveness of the subject to at least one therapeutically active agent usable in treating PAH; and effecting pulmonary artery denervation in a subject responsive to the active agent(s).
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: May 3, 2022
    Assignee: Sonivie Ltd.
    Inventors: Or Shabtay, Dalit Shav
  • Patent number: 11311551
    Abstract: Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: April 26, 2022
    Assignee: REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Carl W. Cotman, Larry E. Overman, Shikha Snigdha